Post results conference call with investors / analysts
Cadila Healthcare Ltd has informed BSE regarding "Post results conference call with investors / analysts".11-05-2016
11-05-2016
Zydus Cadila gets USFDA nod to sell generic diabetes drug
The group has received final approval from USFDA to market the drug in strengths of 1.25, 2.5 and 5 mg, Zydus Cadila said in a statement.11-05-2016
Zydus receives final approval from the USFDA for Glyburide Tablets
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated May 11, 2016 titled "Zydus receives final approval from the USFDA for Glyburide Tablets".11-05-2016
Sell Cadila Healthcare with a target of Rs 305: Mitesh Thacker
The stock was trading at Rs 415.80 at the time the analyst made the recommendation. The stock has been declining since the last week of April.06-05-2016
Cadila Healthcare plans to raise Rs 18,500 cr
Zydus Cadila group firm Cadila Healthcare today said it is planning to raise up to Rs 18,500 crore through issuance of shares and various other securities. The board of directors at its meeting to ...30-04-2016
Updates on ensuing Board Meeting on May 13, 2016
With reference to the earlier letter dated April 25, 2016, Cadila Healthcare Ltd has now informed BSE that the Board of Directors [the Board] at its meeting to be held on May 13, 2016, will also consider the following proposals for raising funds / issuance of securities, which will be subject to approval of the members:1. to raise funds by issue of Equity Shares / convertible Bonds / Debentures through Qualified Institutional Placement [QIP]...30-04-2016
FY16 results on May 13, 2016
Cadila Healthcare Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 13, 2016, inter alia, to consider & approve the audited financial results for the year ended on March 31, 2016.Further, as per Code of Conduct for prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, the Trading Window will remain closed from May 02, 2016 to May 15,...25-04-2016
Deepak Parekh, Pawan Munjal on shortlist for next IIM-A chairman
Pankaj Patel, CMD, Cadila Healthcare to be interim chairman until successor to A M Naik finalised20-04-2016
Shareholding for the Period Ended March 31, 2016
Cadila Healthcare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2016. For more details, kindly Click here08-04-2016
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended March 31, 2016
Cadila Healthcare Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended March 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.06-04-2016